Protocol No
ALLOVIR-P-105-202-PREVENTION
Principal Investigator
Mehdi Hamadani
Phase
II/III
Summary
The purpose of this study is to compare the safety and efficacy of the investigational product, ALVR,(Virlyam-M), and placebo to find out which is better at preventing these viral infections and/or related diseases. This study will also check for development of virus-specific T cells in your blood
Description
Phase II/III Study of ALVR105 After Allogeneic Hematopoietic Cell Transplant
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov